Annual Report (Form 10-K), fiscal year 1994

Item 1. BUSINESS
GENERAL
Johnson & Johnson, employing approximately 81,600 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnson & Johnson's primary interest, both historically and currently, has been in products related to health and well-being.
Johnson & Johnson is organized on the principles of decentralized management. The Executive Committee of Johnson & Johnson is the principal management group responsible for the operations of Johnson & Johnson. In addition, three Executive Committee members are Chairmen of Sector Operating Committees, which are comprised of managers who represent key operations within the sector, as well as management expertise in other specialized functions. These Committees oversee and coordinate the activities of domestic and international companies related to each of the consumer, pharmaceutical, professional and diagnostic businesses. Operating management of each company is headed by a President, General Manager or Managing Director who reports directly or through a Company Group Chairman. In line with this policy of decentralization, each international subsidiary is, with some exceptions, managed by citizens of the country where it is located.
SEGMENTS OF BUSINESS; GEOGRAPHIC AREAS
Johnson & Johnson's worldwide business is divided into three segments: Consumer, Pharmaceutical and Professional. Johnson & Johnson further categorizes its sales and operating profit by major geographic areas of the world. The narrative and tabular (but not the graphic) descriptions of segments and geographic categories captioned "Management's Discussion and Analysis of Results of Operations and Financial Condition -- Segments of Business, Consumer, Pharmaceutical, Professional and Geographic Areas" on pages 26 through 28 and 41 of Johnson & Johnson's annual report to stockholders for fiscal year 1993 are incorporated herein by reference thereto.
CONSUMER
The Consumer segment's principal products are toiletries and hygienic products, including dental and baby care products, first aid products, nonprescription drugs, sanitary protection products and adult incontinence products. Major brands include ACT Fluoride Rinse; BAND-AID Brand Adhesive Bandages; CAREFREE Panty Shields; 'o.b.' Tampons; CLEAN & CLEAR Skin Care Products; SHOWER TO SHOWER toiletries products; STAYFREE and SURE & NATURAL sanitary protection products; IMODIUM A-D, an antidiarrheal; JOHNSON'S baby products; MONISTAT 7, an over-the counter remedy for vaginal yeast infections; MYLANTA gastrointestinal products from the Johnson & Johnson and Merck & Co., Inc. joint venture; PEDIACARE children's cold and allergy medications; PENATEN and NATUSAN baby toiletries; PIZ BUIN and SUNDOWN sun care products; PREVENT and REACH toothbrushes; SERENITY incontinence products; and the broad family of TYLENOL acetaminophen products. These products are marketed principally to the general public and distributed both to wholesalers and directly to independent and chain retail outlets.
PHARMACEUTICAL
The Pharmaceutical segment's principal worldwide franchises are in the allergy and asthma, antifungal, central nervous system, contraceptive, dermatology, gastrointestinal, immunobiology and biotech fields. These products are distributed both directly and through wholesalers for use by health care professionals and the general public. Prescription drugs include DURAGESIC, a transdermal patch for chronic pain; EPREX (sold in the U.S. as PROCRIT), a biotechnology derived version of the human hormone erythropoietin, which stimulates red blood cell production; ERGAMISOL, a colon cancer drug; FLOXIN, an antibacterial; HISMANAL, the once-a-day less sedating antihistamine; IMODIUM, an antidiarrheal; LEUSTATIN, for hairy cell leukemia; MOTILIUM, a gastrointestinal mobilizer; NIZORAL, SPORANOX and TERAZOL, antifungals; ORTHOCLONE OKT-3, for reversing the rejection of kidney transplants; ORTHO-NOVUM group of oral contraceptives; PREPULSID (sold in the U.S. as PROPULSID), a gastrointestinal prokinetic; and RETIN-A, a dermatological cream for acne.
PROFESSIONAL
The Professional segment includes suture and mechanical wound closure products, less-invasive surgical instruments, dental products, diagnostic products, medical equipment and devices, ophthalmic products, surgical instruments, joint replacements and products for wound management and infection prevention. These products are used principally in the professional fields by physicians, dentists, nurses, therapists, hospitals, diagnostic laboratories and clinics. Distribution to these markets is done both directly and through surgical supply and other dealers.
INTERNATIONAL
The international business of Johnson & Johnson is conducted by subsidiaries manufacturing in 43 countries outside the United States and selling in most countries of the world. The products made and sold in the international business include many of those described above under "Business--Consumer, Pharmaceutical and Professional." However, the principal markets, products and methods of distribution in the international business vary with the country and the culture. The products sold in the international business include not only those which were developed in the United States but also those which were developed by subsidiaries abroad.
Investments and activities in some countries outside the United States are subject to higher risks than comparable domestic activities because the investment and commercial climate is influenced by restrictive economic policies and political uncertainties.
RAW MATERIALS
Raw materials essential to Johnson & Johnson's business are generally readily available from multiple sources.
PATENTS AND TRADEMARKS
Johnson & Johnson has made a practice of obtaining patent protection on its products and processes where possible. Johnson & Johnson owns or is licensed under a number of patents relating to its products and manufacturing processes, which in the aggregate are believed to be of material importance in the operation of its business. However, it is believed that no single patent or related group of patents is material in relation to Johnson & Johnson as a whole.
Johnson & Johnson has made a practice of selling its products under trademarks and of obtaining protection for these trademarks by all available means. Johnson & Johnson's major trademarks are protected by registration in the United States and other countries where its products are marketed. Johnson & Johnson considers these trademarks in the aggregate to be of material importance in the operation of its business.
SEASONALITY
Worldwide sales do not reflect any significant degree of seasonality; however spending has been heavier in the fourth quarter of each year than in other quarters. This reflects increased spending decisions, principally for advertising and research grants.
COMPETITION
In each of its segments, Johnson & Johnson companies compete with companies both large and small, located in the United States and abroad. Competition is strong in all segments without regard to the number and size of the competing companies involved. Competition in research, involving the development of new products and processes and the improvement of existing products and processes, is particularly significant and results from time to time in product and process obsolescence. The development of new and improved products is important to Johnson & Johnson's success in all areas of its business. This competitive environment requires substantial investments in continuing research and in multiple sales forces. In addition, the winning and retention of customer acceptance of Johnson & Johnson's consumer products involve heavy expenditures for advertising, promotion and selling.
RESEARCH
Research activities are important to all segments of Johnson & Johnson's business. Major research facilities are located not only in the United States but also in Australia, Belgium, Brazil, Canada, Switzerland, the United Kingdom and Germany. The costs of Johnson & Johnson's worldwide research activities relating to the development of new products, the improvement of existing products, technical support of products and compliance with governmental regulations for the protection of the consumer amounted to $1,182; $1,127 and $980 million for fiscal years 1993, 1992 and 1991, respectively. These costs are charged directly to income in the year in which incurred. All research was sponsored by Johnson & Johnson.
ENVIRONMENT
During the past year Johnson & Johnson was subject to a variety of Federal, state and local environmental protection measures. Johnson & Johnson believes that its operations comply in all material respects with applicable environmental laws and regulations. Johnson & Johnson's compliance with these requirements did not and is not expected to have a material effect upon its capital expenditures, earnings or competitive position.
REGULATION
Most of Johnson & Johnson's business is subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward regulation of increasing stringency. In the United States, the drug, device, diagnostics and cosmetic industries have long been subject to regulation by various federal, state and local agencies, primarily as to product safety, efficacy, advertising and labeling. The exercise of broad regulatory powers by the Food and Drug Administration (the "FDA") continues to result in increases in the amounts of time, testing and documentation required for FDA clearance of new drugs and devices and a corresponding increase in the expense of product introduction. In addition, reapproval and reporting requirements with respect to broad classes of medical devices and diagnostics may result in an increase in the expense required to maintain some existing products on the market. Similar trends toward product and process regulation are also evident in a number of major countries outside of the United States, especially in the European Economic Community where efforts are continuing to harmonize the internal regulatory systems.
The costs of human health care have been and continue to be a subject of study and investigation by governmental agencies and legislative bodies in the United States and other countries; most recently in the United States by the Administration's health reform task force. In the United States, attention has been focused on drug prices and profits and programs to encourage doctors to write prescriptions that can or must be filled with generic substitutes rather than with drugs bearing a specified trademark. It is likely that increased attention will be paid to drug pricing and appropriate drug utilization. For example, the 1990 Omnibus Budget Reconciliation Act included a provision requiring pharmaceutical companies to rebate to states a portion of the revenues from pharmaceutical products dispensed to state Medicaid recipients. The Veterans Health Care Act of 1992 granted state and local facilities receiving Public Health Service Funds the right to purchase drugs at Medicaid prices. The same Act mandated discount prices for drug sales to the Department of Veterans Affairs and other Federal Supply Schedule purchasers.
Further, the Federal government has established a diagnosis related group ("DRG") payment system for certain institutional services provided under Medicare or Medicaid. The DRG system entitles an institution to a fixed amount (based on discharge diagnosis) for operating costs incurred in treatment of each Medicare or Medicaid beneficiary. Under prior law, payments for such services had been predicated almost entirely on reimbursement of the allowable historical costs of the individual hospital or health care facility providing the services. The DRG payment system has resulted in increased incentives for health care facilities to limit or control expenditures for many of the products sold by Johnson & Johnson. Johnson & Johnson encounters regulations and legislation similar to the foregoing in most of the countries where it does business.
The regulatory agencies under whose purview Johnson & Johnson operates have administrative powers that may subject Johnson & Johnson to such actions as product recalls, seizure of products and other civil and criminal sanctions. In some cases Johnson & Johnson may deem it advisable to initiate product recalls voluntarily.
Item 2.



Item 2. PROPERTIES
Johnson & Johnson and its worldwide subsidiaries operate 163 manufacturing facilities occupying approximately 15 million square feet of floor space.
The manufacturing facilities are used by the industry segments of Johnson & Johnson's business approximately as follows:
Square Feet Segment (in thousands) ------- --------------
Consumer...................................... 6,223 Pharmaceutical................................ 2,730 Professional.................................. 6,583 ------ Worldwide total......................... 15,536 ======
Within the United States, 12 facilities are used by the Consumer segment, 8 by the Pharmaceutical segment and 46 by the Professional segment. Johnson & Johnson's manufacturing operations outside the United States are often conducted in facilities which serve more than one segment of the business.
The locations of the manufacturing facilities by major geographic areas of the world are as follows:
Number of Square Feet Geographic Area Facilities (in thousands) --------------- ---------- --------------
United States....................... 61 7,605 Europe.............................. 43 3,572 Western Hemisphere excluding U.S.A.. 20 2,345 Africa, Asia and Pacific............ 39 2,014 --- ------ Worldwide total............... 163 15,536 === ======
In addition to the manufacturing facilities discussed above, Johnson & Johnson maintains numerous office and warehouse facilities throughout the world. Research facilities are also discussed under "Business--Research."
Johnson & Johnson generally seeks to own its manufacturing facilities, although some, principally in locations abroad, are leased. Office and warehouse facilities are often leased.
Johnson & Johnson's properties are maintained in good operating condition and repair and are well utilized.
For information regarding lease obligations see Note 9 under "Johnson & Johnson and Subsidiaries--Notes to Consolidated Financial Statements" on page 34 of Johnson & Johnson's Annual Report to Stockholders for fiscal year 1993. Segment information on additions to Johnson & Johnson's property, plant and equipment is contained on page 41 of Johnson & Johnson's Annual Report to Stockholders for fiscal year 1993.
Item 3.

Item 3. LEGAL PROCEEDINGS
The information set forth in Note 19 "Pending Legal Proceedings" on page 39 of Johnson & Johnson's Annual Report to Stockholders for fiscal year 1993 is incorporated herein by reference.
The Company or its subsidiaries are parties to a number of administrative and judicial environmental proceedings, including proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state laws. The primary relief sought in these proceedings is the cost of past and future remediation. While it is not feasible to predict or determine the outcome of these proceedings, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the operations or financal position of the Company.
Item 4.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Not applicable.
EXECUTIVE OFFICERS OF THE REGISTRANT
Listed below are the executive officers of Johnson & Johnson as of March 15, 1994, each of whom has been an employee of the Company or its affiliates during the past five years, except as otherwise noted. There are no family relationships between any of the executive officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was selected. At the annual meeting of the Board of Directors which follows the Annual Meeting of Stockholders executive officers are elected by the Board to hold office for one year and until their respective successors are elected and qualified, or until earlier resignation or removal.
Information with regard to the directors of the Company, including those of the following executive officers who are directors, is incorporated by reference to pages 2 through 7 of Johnson & Johnson's Proxy Statement dated March 10, l994.
_________________
(a) Mr. R. S. Fine joined the Company in 1974 and became Assistant General Counsel in 1978 and Associate General Counsel in 1984. He became a Member of the Executive Committee and Vice President, Administration in 1991.
(b) Mr. P. N. Larson joined the Company in 1991 as a Company Group Chairman. He became Chairman of a Sector Operating Committee and a Member of the Executive Committee in 1992. Prior to joining the Company in 1991, Mr. P. N. Larson was a member of a partnership managing consumer businesses. He had previously been employed by Kimberly-Clark Corporation since 1978 in a variety of assignments, including President of their Health Care Sector and member of their Board of Directors.
PART II
Item 5.

Item 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
The information called for by this item is incorporated herein by reference to the material captioned "Management's Discussion and Analysis of Results of Operations and Financial Condition--Common Stock Market Prices and Cash Dividends Paid " on page 24 of Johnson & Johnson's Annual Report to Stockholders for fiscal year 1993.
Item 6.

Item 6. SELECTED FINANCIAL DATA
The information called for by this item is incorporated herein by reference to the material captioned "Summary of Operations and Statistical Data 1983-1993" on page 42 of Johnson & Johnson's Annual Report to Stockholders for fiscal year 1993.
Item 7.

Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The information called for by this item is incorporated herein by reference to the material captioned "Management's Discussion and Analysis of Results of Operations and Financial Condition--Overview, Sales and Earnings, Costs and Expenses, Liquidity and Capital Resources and Changing Prices and Inflation" on pages 23 through 25, of Johnson & Johnson's Annual Report to Stockholders for fiscal year 1993.
Item 8.


Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The information called for by this item is incorporated herein by reference to the consolidated financial statements and the notes thereto and the material captioned "Independent Auditor's Report", on pages 29 through 40 of Johnson & Johnson's Annual Report to Stockholders for fiscal year 1993.
Item 9.

Item 9. DISAGREEMENTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
Not applicable.
PART III
Item 10.



Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Information with respect to executive officers is presented at the end of Part I hereof. Information with respect to directors is incorporated herein by reference to the material captioned "Election of Directors--Nominees" on pages 2 through 7 of Johnson & Johnson's proxy statement dated March 10, 1994.
Item 11.

Item 11. EXECUTIVE COMPENSATION
The information called for by this item is incorporated herein by reference to the material captioned "Election of Directors--Directors' Fees, Committees and Meetings" and "Executive Compensation" on pages 8 and 13 through 16 of Johnson & Johnson's proxy statement dated March 10, 1994.
Item 12.

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information called for by this item is incorporated herein by reference to the material captioned " Information--Principal Stockholder" and "Election of Directors--Nominees and Stock Ownership/Control" on pages 2 through 8 of Johnson & Johnson's proxy statement dated March 10, 1994.
Item 13.

Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Not applicable.
PART IV
Item 14.

Item 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a) 1. Financial Statements
The financial statements to be included in this report are incorporated in Part II, Item 8 hereof by reference to Johnson & Johnson's Annual Report to Stockholders for fiscal year 1993.
2. Financial Statement Schedules
V Property, Plant and Equipment
VI Accumulated Depreciation of Property, Plant and Equipment
VIII Reserves
IX Short Term Borrowings
X Supplementary Income Statement Information
Schedules other than those listed above are omitted because they are not required or are not applicable.
3. Exhibits Required to be Filed by Item 601 of Regulation S-K
The information called for by this paragraph is incorporated herein by reference to the Exhibit Index of this report.
(b) Reports on Form 8-K
No reports on Form 8-K were filed during the last quarter of the period covered by this report.
JOHNSON & JOHNSON AND SUBSIDIARIES SCHEDULE V-PROPERTY, PLANT AND EQUIPMENT Fiscal Years Ended January 2, 1994, January 3, 1993 and December 29, 1991 (Dollars in Millions)
Note A - Includes write-off of fully depreciated assets. Note B - Represents assets of companies acquired during the period. Note C - Represents transfers between account classifications. Note D - Represents the cumulative currency translation adjustment.
JOHNSON & JOHNSON AND SUBSIDIARIES SCHEDULE VI-ACCUMULATED DEPRECIATION OF PROPERTY, PLANT AND EQUIPMENT Fiscal Years Ended January 2, 1994, January 3, 1993 and December 29, 1991 (Dollars in Millions)
Note A - Includes write-off of fully depreciated assets. Note B - Represents transfers between account classifications. Note C - Represents the cumulative currency translation adjustment.
The following estimated useful lives have been used as a basis for the calculation of depreciation on the significant portions of the respective classes of assets:
The cost of improvements to leased properties is written off over the terms of the respective leases or useful lives, whichever is shorter.
The cost of maintenance, repairs, and renewals is charged against income in the year in which incurred, while the cost of betterments and replacements is capitalized by charges to the respective asset accounts.
Upon retirement or other disposal of fixed assets, the cost and related amount of accumulated depreciation or amortization are eliminated from the asset and reserve accounts respectively. The difference, if any, between the net asset value and the proceeds is adjusted to income. The cost of assets still in use which have been fully depreciated is eliminated from the asset and related reserve accounts.
JOHNSON & JOHNSON AND SUBSIDIARIES
SCHEDULE VIII - RESERVES
Fiscal Years Ended January 2, 1994, January 3, 1993 and December 29, 1991 (Dollars in Millions)
(1) Charges related to customer rebates and cash discounts are reflected as reductions of sales to customers. q
JOHNSON & JOHNSON AND SUBSIDIARIES
SCHEDULE IX - SHORT TERM BORROWINGS
Fiscal Years Ended January 2, 1994, January 3, 1993 and December 29, 1991 (Dollars in Millions)
Note A - Consists primarily of international notes payable to banks. Note B - Reflects five quarter average balance. Note C - Reflects five quarter average balance and related interest expense for the year.
JOHNSON & JOHNSON AND SUBSIDIARIES
SCHEDULE X - SUPPLEMENTARY INCOME STATEMENT INFORMATION
Fiscal Years Ended January 2, 1994, January 3, 1993 and December 29, 1991 (Dollars in Millions)
SIGNATURES
Pursuant to the requirements of Section 13 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: March 28, 1994 JOHNSON & JOHNSON ----------------------------------------- (Registrant)
By /S/ R. S. Larsen ----------------------------------------- R. S. Larsen, Chairman, Board of Directors and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been duly signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
REPORT OF INDEPENDENT AUDITORS
To the Stockholders and Board of Directors of Johnson & Johnson:
Our report on the consolidated financial statements of Johnson & Johnson and subsidiaries has been incorporated by reference in this Form 10-K from the Johnson & Johnson 1993 Annual Report to Stockholders and appears on page 40 therein. In connection with our audits of such financial statements, we have also audited the related financial statement schedules listed in the index in Item 14 of this Form 10-K.
In our opinion, the financial statement schedules referred to above, when considered in relation to the basic financial statements taken as a whole, present fairly, in all material respects, the information required to be included therein.
COOPERS & LYBRAND
New York, New York January 31, 1994
CONSENT OF INDEPENDENT AUDITORS
We hereby consent to the incorporation by reference in Registration Statements No. 33-52260, 33-40294, 33-40295, 33-32875, 2-67443, 2-77153, 2-78905 and 33-7634 on Form S-8 and No. 33-47424 and 33-37040 on Form S-3 and related Prospectuses of our report dated January 31, 1994 on our audits of the consolidated financial statements and financial statement schedules of Johnson & Johnson and subsidiaries as of January 2, 1994 and January 3, 1993, and for each of the three years in the period ended January 2, 1994, which reports are included or incorporated by reference in this Annual Report on Form 10-K.
COOPERS & LYBRAND
New York, New York January 31, 1994
EXHIBIT INDEX
Reg. S-K Exhibit Table Description Item No. of Exhibit ------------- ----------- 3(a) Certificate of Amendment to the Restated Certificate of Incorporation of the Company and Restated Certificate of Incorporation, dated May 20, 1992 -- Incorporated herein by reference to Exhibit 3(a) of the Registrant's Form 10-K Annual Report for the year ended January 3, 1993.
3(b) By-Laws of the Company, as amended April 26, 1990 -- Incorporated herein by reference to Exhibit 3(b) of the Registrant's Form 10-K Annual Report for the year ended January 3, 1993.
10(a) 1991 Stock Option Plan -- Incorporated by reference to Registration Statement No. 33-40294, Exhibit 4(a).*
10(b) 1986 Stock Option Plan (as amended) -- Incorporated herein by reference to Exhibit 10(b) of the Registrant's Form 10-K Annual Report for the year ended January 3, 1993.*
10(c) 1981 Incentive Stock Option Plan (as amended) -- Incorporated herein by reference to Exhibit 10(c) of the Registrant's Form 10-K Annual Report for the year ended January 3, 1993.*
10(d) 1980 Stock Option Plan (as amended) -- Incorporated herein by reference to Exhibit 10(d) of the Registrant's Form 10-K Annual Report for the year ended January 3, 1993.*
10(e) 1991 Stock Compensation Plan -- Incorporated herein by reference to Exhibit 10(e) of the Registrant's Form 10-K Annual Report for the year ended January 3, 1993.*
10(f) 1986 Stock Compensation Plan -- Incorporated herein by reference to Exhibit 10(f) of the Registrant's Form 10-K Annual Report for the year ended January 3, 1993.*
10(g) Domestic Deferred Compensation Plan -- Incorporated herein by reference to Exhibit 10(g) of the Registrant's Form 10-K Annual Report for the year ended January 3, 1993.*
10(h) Supplemental Retirement Plan -- Incorporated herein by reference to Exhibit 10(h) of the Registrant's Form 10-K Annual Report for the year ended January 3, 1993.*
10(i) Executive Life Insurance Plan -- Incorporated herein by reference to Exhibit 10(i) of the Registrant's Form 10-K Annual Report for the year ended January 3, 1993.*
11 -Calculation of Earnings Per Share -- Filed with this document.
12 -Statement of Computation of Ratio of Earnings to Fixed Charges -- Filed with this document.
13 -Annual report to stockholders for fiscal year 1993 (only those portions incorporated by reference in this document are deemed "filed") -- Filed with this document.
21 -Subsidiaries -- Filed with this document.
28 -Form 11-K for the Johnson & Johnson Savings Plan to be filed on or before June 30, 1994.
* Management contracts and compensatory plans and arrangements required to be filed as exhibits to this form pursuant to Item 14(c) of this report.
A copy of any of the exhibits listed above will be provided without charge to any stockholder submitting a written request specifying the desired exhibit(s) to the Secretary at the principal executive offices of the Company.